Summary

In a randomized placebo-controlled trial, adults and adolescents with active EoE both histologically and symptomatically were given either oral budesonide or placebo for 12 weeks. Using a validated symptom tool and biopsy data, the results suggest a significant improvement in both symptoms and histology among those in the budesonide group, with no impending safety signals.